Search
forResearch 10 of 1000+
- Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia
- From Piezoelectric Nanogenerator to Non-Invasive Medical Sensor: A Review
- Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
- CARDIOVASCULAR SAFETY OF LOW-DOSE ORAL MINOXIDIL FOR ANDROGENETIC ALOPECIA IN PATIENTS WITH HYPERTENSION OR ARRHYTHMIAS
- Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors in Early Onset Male Androgenetic Alopecia - A Cross Sectional Study in a Tertiary Care Hospital
- Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations
- Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia
- The efficacy and safety of oral minoxidil greater than 5 mg daily in hair loss disorders
- Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil
- Gender-Affirming Hormone Therapy for Transgender Men
Community 5 of 21
- Being Safe on Oral Minoxidil: tl;dr on the literature.
- How Dangerous is Oral Min Really?
- Anyone read oral minoxidil's leaflet?
- Pattern hair loss before the age of 35 is associated with higher chances of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life
- Has anyone figured out what causes the cardiovascular issues with RU?